Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis

Systemic Lupus Erythematosus

Efficacy and safety of rituximab in comparison with common induction therapies in pediatric active lupus nephritis

Pediatr Nephrol.

Basu B, Roy B, Babu BG

doi: 10.1007/s00467-017-3583-x.

Psoriatic Arthritis

Comparative efficacy and safety of targeted DMARDs for active psoriatic arthritis during induction therapy: A systematic review and network meta-analysis

Semin Arthritis Rheum.

Lu C, Wallace BI, Waljee AK, Fu W, Zhang Q, Liu Y

doi: 10.1016/j.semarthrit.

Psoriasis

Tofacitinib: A New Oral Therapy for Psoriasis

Clin Drug Investig.

Azevedo A, Torres T

doi: 10.1007/s40261-017-0596-y.

Melanoma and Skin Cancer

Re-induction ipilimumab following acquired resistance to combination ipilimumab and anti-PD-1 therapy

Eur J Cancer

Hepner A, Atkinson VG, Larkin J, Burrell RA, Carlino MS, Johnson DB, Zimmer L, Tsai KK, Klein O, Lo SN, Haydon A, Bhave P, Lyle M, Pallan L, Pires da Silva I, Gerard C, Michielin O, Long GV, Menzies AM

doi: 10.1016/j.ejca.2021.04.021

Rheumatoid Arthritis

Switching from TNFα inhibitor to tacrolimus as maintenance therapy in rheumatoid arthritis after achieving low disease activity with TNFα inhibitors and methotrexate: 24-week result from a non-randomized, prospective, active-controlled trial

Arthritis Res Ther

Jung SY, Koh JH, Kim KJ, Park YW, Yang HI, Choi SJ, Lee J, Choi CB, Kim WU

doi: 10.1186/s13075-021-02566-z

Biologics and immunomodulators for treating Crohn's disease developing after surgery for an initial diagnosis of ulcerative colitis: a review of current literature

Scand J Gastroenterol.

Yadav A, Foromera J, Falchuk KR, Feuerstein JD

doi: 10.1080/00365521.

Rheumatoid Arthritis

Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trialv

Lancet.

Fleischmann R, Mysler E, Hall S, Kivitz AJ, Moots RJ, Luo Z, DeMasi R, Soma K, Zhang R, Takiya L, Tatulych S, Mojcik C, Krishnaswami S, Menon S, Smolen JS; ORAL Strategy investigators

doi: 10.1016/

Acne

Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials

Lancet

Danese S, Vermeire S, Zhou W, Pangan AL, Siffledeen J, Greenbloom S, Hébuterne X, D'Haens G, Nakase H, Panés J, Higgins PDR, Juillerat P, Lindsay JO, Loftus EV Jr, Sandborn WJ, Reinisch W, Chen MH, Sanchez Gonzalez Y, Huang B, Xie W, Liu J, Weinreich MA, Panaccione R

doi: 10.1016/S0140-6736(22)00581-5

Further Publications Immunology

Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis?

Ann Rheum Dis.

Baker KF, Isaacs JD

doi: 10.1136/

Related content